Portal de Periódicos da CAPES

Hodgkin’s Disease: The Milan Cancer Institute Experience with MOPP and ABVD

1989; Springer Science+Business Media; Linguagem: Inglês

10.1007/978-3-642-83781-4_17

2197-6767

Gianni Bonadonna, Pinuccia Valagussa, Armando Santoro, Simonetta Viviani, V. Bonfante, Alberto Banfi,

Cancer Treatment and Pharmacology

This paper briefly reports the Milan Cancer Institute experience on Hodgkin's disease treated with an Adriamycin- and bleomycin-based combination (ABVD: Adriamycin, bleomycin, vinblastine, and dacarbazine). Following the initial publication on MOPP (mustine, oncovin, procarbazine, and prednisone) chemotherapy (De Vita et al. 1970), many investigators including ourselves have attempted to improve further the therapeutic results by modifying the original drug combination. Published findings have indicated that none of the modified MOPP regimens has indeed achieved superior results (Bonadonna and Santoro 1982). In 1974, we developed a four-drug combination (ABVD) whose components were totally different from those included in the MOPP combination. Our aim was to utilize ABVD in MOPP-resistant patients. Through successive randomized studies we have gained experience on the efficacy of ABVD alternated with MOPP and tested versus MOPP within a combined modality treatment.